Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization

Po Ting Lin; Wei Teng; Wen Juei Jeng; Wei Ting Chen; Yi Chung Hsieh; Chien Hao Huang; Kar Wai Lui; Chen Fu Hung; Ching Ting Wang; Pei Mei Chai; Chen Chun Lin; Chun Yen Lin; Shi Ming Lin; I. Shyan Sheen

doi:10.3390/diagnostics12030665

Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization

Po Ting Lin, Wei Teng^*, Wen Juei Jeng, Wei Ting Chen, Yi Chung Hsieh, Chien Hao Huang, Kar Wai Lui, Chen Fu Hung, Ching Ting Wang, Pei Mei Chai, Chen Chun Lin, Chun Yen Lin^*, Shi Ming Lin, I. Shyan Sheen

^*此作品的通信作者

醫學系

研究成果: 期刊稿件 › 文章 › 同行評審

5 引文斯高帕斯（Scopus）

摘要

Background and Aims: The Albumin-Bilirubin (ALBI) grade is a good index for liver function evaluation and is also associated with the outcomes of hepatocellular carcinoma patients receiving TACE. However, the correlation between the dynamic change to the ALBI score and clinical outcome is seldom discussed. Therefore, this study aimed to investigate the application of ALBI grade and dynamic change of ALBI grade (delta ALBI grade) after first TACE for prognosis prediction in HCC patients with chronic hepatitis C infection. Method: From January 2005 to December 2015, newly diagnosed naive chronic hepatitis C-hepatocellular carcinoma (CHC-HCC) patients who were treated with TACE as the initial treatment at the Chang Gung Memorial Hospital, Linkou Medical Center, were retrospectively recruited. The pre-treatment host factors, tumor status and noninvasive markers were collected. The Cox regression model was used to identify independent predictors of overall survival and tumor recurrence. Results: Among 613 treatment-naive CHC-HCC patients, 430 patients died after repeated TACE during a median follow-up of 26.9 months. Complete remission after repeated TACE occurred in 46.2% patients, and 208 patients (33.9%) had tumor recurrence, with a median recurrence-free interval of 8.5 months. In Cox regression analysis, ALBI grade II/III (aHR: 1.088, p = 0.035) and increased delta ALBI grade (aHR: 1.456, p = 0.029) were independent predictive factors for tumor recurrence. Furthermore, ALBI grade II/III (aHR: 1.451, p = 0.005) and increased delta ALBI grade during treatment (aHR: 1.436, p = 0.006) were predictive factors for mortality, while achieving complete response after repeated TACE (aHR: 0.373, p < 0.001) and anti-viral therapy (aHR: 0.580, p = 0.002) were protective factors for mortality. Conclusion: Both ALBI and delta ALBI grade are independent parameters to predict survival and tumor recurrence of CHC-HCC patients receiving TACE treatment.

原文	英語
文章編號	665
期刊	Diagnostics
卷	12
發行號	3
DOIs	https://doi.org/10.3390/diagnostics12030665
出版狀態	已出版 - 03 2022

文獻附註

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.3390/diagnostics12030665

其它文件與鏈接

Link to publication in Scopus

引用此

Lin, P. T., Teng, W., Jeng, W. J., Chen, W. T., Hsieh, Y. C., Huang, C. H., Lui, K. W., Hung, C. F., Wang, C. T., Chai, P. M., Lin, C. C., Lin, C. Y., Lin, S. M., & Sheen, I. S. (2022). Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. Diagnostics, 12(3), 文章 665. https://doi.org/10.3390/diagnostics12030665

@article{e8c51337019c438b853685634b48b627,

title = "Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization",

abstract = "Background and Aims: The Albumin-Bilirubin (ALBI) grade is a good index for liver function evaluation and is also associated with the outcomes of hepatocellular carcinoma patients receiving TACE. However, the correlation between the dynamic change to the ALBI score and clinical outcome is seldom discussed. Therefore, this study aimed to investigate the application of ALBI grade and dynamic change of ALBI grade (delta ALBI grade) after first TACE for prognosis prediction in HCC patients with chronic hepatitis C infection. Method: From January 2005 to December 2015, newly diagnosed naive chronic hepatitis C-hepatocellular carcinoma (CHC-HCC) patients who were treated with TACE as the initial treatment at the Chang Gung Memorial Hospital, Linkou Medical Center, were retrospectively recruited. The pre-treatment host factors, tumor status and noninvasive markers were collected. The Cox regression model was used to identify independent predictors of overall survival and tumor recurrence. Results: Among 613 treatment-naive CHC-HCC patients, 430 patients died after repeated TACE during a median follow-up of 26.9 months. Complete remission after repeated TACE occurred in 46.2% patients, and 208 patients (33.9%) had tumor recurrence, with a median recurrence-free interval of 8.5 months. In Cox regression analysis, ALBI grade II/III (aHR: 1.088, p = 0.035) and increased delta ALBI grade (aHR: 1.456, p = 0.029) were independent predictive factors for tumor recurrence. Furthermore, ALBI grade II/III (aHR: 1.451, p = 0.005) and increased delta ALBI grade during treatment (aHR: 1.436, p = 0.006) were predictive factors for mortality, while achieving complete response after repeated TACE (aHR: 0.373, p < 0.001) and anti-viral therapy (aHR: 0.580, p = 0.002) were protective factors for mortality. Conclusion: Both ALBI and delta ALBI grade are independent parameters to predict survival and tumor recurrence of CHC-HCC patients receiving TACE treatment.",

keywords = "Albumin, Alpha-fetoprotein, Bilirubin, Hepatitis, Hepatocellular carcinoma, Liver, Survival",

author = "Lin, {Po Ting} and Wei Teng and Jeng, {Wen Juei} and Chen, {Wei Ting} and Hsieh, {Yi Chung} and Huang, {Chien Hao} and Lui, {Kar Wai} and Hung, {Chen Fu} and Wang, {Ching Ting} and Chai, {Pei Mei} and Lin, {Chen Chun} and Lin, {Chun Yen} and Lin, {Shi Ming} and Sheen, {I. Shyan}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

doi = "10.3390/diagnostics12030665",

language = "英语",

volume = "12",

journal = "Diagnostics",

issn = "2075-4418",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

Lin, PT, Teng, W, Jeng, WJ, Chen, WT, Hsieh, YC, Huang, CH, Lui, KW, Hung, CF, Wang, CT, Chai, PM, Lin, CC, Lin, CY, Lin, SM & Sheen, IS 2022, 'Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization', Diagnostics, 卷 12, 編號 3, 665. https://doi.org/10.3390/diagnostics12030665

TY - JOUR

T1 - Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization

AU - Lin, Po Ting

AU - Teng, Wei

AU - Jeng, Wen Juei

AU - Chen, Wei Ting

AU - Hsieh, Yi Chung

AU - Huang, Chien Hao

AU - Lui, Kar Wai

AU - Hung, Chen Fu

AU - Wang, Ching Ting

AU - Chai, Pei Mei

AU - Lin, Chen Chun

AU - Lin, Chun Yen

AU - Lin, Shi Ming

AU - Sheen, I. Shyan

PY - 2022/3

Y1 - 2022/3

N2 - Background and Aims: The Albumin-Bilirubin (ALBI) grade is a good index for liver function evaluation and is also associated with the outcomes of hepatocellular carcinoma patients receiving TACE. However, the correlation between the dynamic change to the ALBI score and clinical outcome is seldom discussed. Therefore, this study aimed to investigate the application of ALBI grade and dynamic change of ALBI grade (delta ALBI grade) after first TACE for prognosis prediction in HCC patients with chronic hepatitis C infection. Method: From January 2005 to December 2015, newly diagnosed naive chronic hepatitis C-hepatocellular carcinoma (CHC-HCC) patients who were treated with TACE as the initial treatment at the Chang Gung Memorial Hospital, Linkou Medical Center, were retrospectively recruited. The pre-treatment host factors, tumor status and noninvasive markers were collected. The Cox regression model was used to identify independent predictors of overall survival and tumor recurrence. Results: Among 613 treatment-naive CHC-HCC patients, 430 patients died after repeated TACE during a median follow-up of 26.9 months. Complete remission after repeated TACE occurred in 46.2% patients, and 208 patients (33.9%) had tumor recurrence, with a median recurrence-free interval of 8.5 months. In Cox regression analysis, ALBI grade II/III (aHR: 1.088, p = 0.035) and increased delta ALBI grade (aHR: 1.456, p = 0.029) were independent predictive factors for tumor recurrence. Furthermore, ALBI grade II/III (aHR: 1.451, p = 0.005) and increased delta ALBI grade during treatment (aHR: 1.436, p = 0.006) were predictive factors for mortality, while achieving complete response after repeated TACE (aHR: 0.373, p < 0.001) and anti-viral therapy (aHR: 0.580, p = 0.002) were protective factors for mortality. Conclusion: Both ALBI and delta ALBI grade are independent parameters to predict survival and tumor recurrence of CHC-HCC patients receiving TACE treatment.

AB - Background and Aims: The Albumin-Bilirubin (ALBI) grade is a good index for liver function evaluation and is also associated with the outcomes of hepatocellular carcinoma patients receiving TACE. However, the correlation between the dynamic change to the ALBI score and clinical outcome is seldom discussed. Therefore, this study aimed to investigate the application of ALBI grade and dynamic change of ALBI grade (delta ALBI grade) after first TACE for prognosis prediction in HCC patients with chronic hepatitis C infection. Method: From January 2005 to December 2015, newly diagnosed naive chronic hepatitis C-hepatocellular carcinoma (CHC-HCC) patients who were treated with TACE as the initial treatment at the Chang Gung Memorial Hospital, Linkou Medical Center, were retrospectively recruited. The pre-treatment host factors, tumor status and noninvasive markers were collected. The Cox regression model was used to identify independent predictors of overall survival and tumor recurrence. Results: Among 613 treatment-naive CHC-HCC patients, 430 patients died after repeated TACE during a median follow-up of 26.9 months. Complete remission after repeated TACE occurred in 46.2% patients, and 208 patients (33.9%) had tumor recurrence, with a median recurrence-free interval of 8.5 months. In Cox regression analysis, ALBI grade II/III (aHR: 1.088, p = 0.035) and increased delta ALBI grade (aHR: 1.456, p = 0.029) were independent predictive factors for tumor recurrence. Furthermore, ALBI grade II/III (aHR: 1.451, p = 0.005) and increased delta ALBI grade during treatment (aHR: 1.436, p = 0.006) were predictive factors for mortality, while achieving complete response after repeated TACE (aHR: 0.373, p < 0.001) and anti-viral therapy (aHR: 0.580, p = 0.002) were protective factors for mortality. Conclusion: Both ALBI and delta ALBI grade are independent parameters to predict survival and tumor recurrence of CHC-HCC patients receiving TACE treatment.

KW - Albumin

KW - Alpha-fetoprotein

KW - Bilirubin

KW - Hepatitis

KW - Hepatocellular carcinoma

KW - Liver

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85126434986&partnerID=8YFLogxK

U2 - 10.3390/diagnostics12030665

DO - 10.3390/diagnostics12030665

M3 - 文章

AN - SCOPUS:85126434986

SN - 2075-4418

VL - 12

JO - Diagnostics

JF - Diagnostics

IS - 3

M1 - 665

ER -

Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization

摘要

文獻附註

UN SDG

存取文件

其它文件與鏈接

指紋

引用此